Hoth Therapeutics, which is a biotech developing therapies for eczema, announced terms for its IPO on Thursday.
The New York, NY-based company plans to raise $11 million by offering 1.8 million shares at a price range of $5.50 to $6.50. At the midpoint of the proposed range, Hoth Therapeutics would command a fully diluted market value of $91 million.
Hoth Therapeutics was founded in 2017 and plans to list on the Nasdaq under the symbol HOTH. The Benchmark Company is the sole bookrunner on the deal.
